Contact: Tedra White
Web Site: www.promedica.org
ProMedica Toledo Hospital Offers the Industry's Most Innovative Tools For Detecting Breast Cancer
posted on: 12/03/2013
Dr. Robin Shermis is the medical director of the ProMedica Toledo Hospital Breast Care Center and a board-certified radiologist specializing in breast imaging.
TOLEDO, Ohio, Oct. 24, 2013 – During Breast Cancer Awareness Month women are reminded of the importance of getting regular screening mammograms, depending on their age and individual risk factors. However, for those with dense breast tissue, a mammogram alone may not be enough.
Fortunately, radiologists at ProMedica Toledo Hospital Breast Care Center have a new tool to help evaluate breast tissue density on a mammogram. It’s called VolparaDensity™, a breast imaging software tool that uses complex physics and software to measure the amount of tissue within a patient’s breast. This information is used by a breast imaging radiologist to decide if additional breast screening, beyond a mammogram, might be necessary. Additional breast screening tools include magnetic resonance imaging (MRI) and molecular breast imaging (MBI).
According to the American Cancer Society, approximately 40 percent of all women have dense breast tissue. A dense breast has more tissue than fat. Dense breasts make it difficult to detect breast cancer on a mammogram because breast tissue and cancer can both appear white. Experts compare it to trying to identify a snowball in a snow storm. As a result, 35 percent of breast cancer goes undetected in these patients.
Toledo Hospital is the first hospital in Ohio to offer VolparaDensity. The center’s medical director Robin Shermis, MD, says VolparaDensity was selected because it offers a consistent and standardized approach to calculating breast density when used in conjunction with the radiologist.
“We evaluated other commercially available density measurement tools, but adopted VolparaDensity because it has been proven to offer a reliable and objective volumetric measurement,” says Dr. Shermis. “Our patients can take comfort in knowing that when they come to our center, they will be thoroughly assessed and vectored to additional screening in our effort to improve the early detection of cancer.”
Cleared by the Food and Drug Administration (FDA), VolparaDensity is in use at sites around the world. It was developed by Matakina International based in New Zealand. The company’s mission is to improve the detection and diagnosis of breast cancer.
Toledo Hospital’s Breast Care Center is devoted exclusively to patients with breast health issues. It is recognized as a Breast Imaging Center of Excellence by the American College of Radiology for meeting the highest standards of the radiology profession and achieving accreditation in mammography, breast ultrasound, ultrasound-guided biopsy and stereotactic breast biopsy. In 2011, the center introduced the LumaGEM™ MBI system, the industry’s first commercially available, dual head digital imaging system. MBI requires less radiation and provides higher quality images that are easier to interpret.
“The MBI technology compliments our state-of-the-art MRI program,” says Dr. Shermis.
For more information about ProMedica Toledo Hospital Breast Care Center, visit www.promedica.org/breastcare.
ProMedica Toledo Hospital is a member of Toledo, Ohio-based ProMedica, a mission-based, not-for-profit healthcare organization formed in 1986. ProMedica has more than 14,400 employees and nearly 1,700 physicians – with more than 450 healthcare providers employed by ProMedica Physicians. Its 11 hospitals and more than 310 facilities offer comprehensive diagnostic, medical and surgical specialties in heart and vascular, oncology, orthopaedics, neurology, and women and pediatric services. ProMedica’s mission is to improve health and well-being, with a strong focus on wellness and clinical excellence, as well as innovative, community advocacy programs that address health-related issues such as hunger and obesity. For more information, please visit www.promedica.org.